Skip to main content
Premium Trial:

Request an Annual Quote

Illumina's Q1 Revenues Rise 148 Percent as R&D Nearly Doubles; Solexa Buy Widens Loss

NEW YORK (GenomeWeb News) — Illumina today said first-quarter revenues increased 148 percent as R&D spending nearly doubled and the company posted a $300 million net loss affected by acquisition-related charges.
 
Total receipts for the three months ended March 31 increased to $72.2 million from $29.1 million year over year.
 
Product revenues nearly tripled, rising to $61.2 million from $21.3 million, while service and other revenue more than doubled to $10.8 million from $5.2 million year over year.
 
R&D spending almost doubled to $16 million from $8.2 million in the year-ago period.
 
Illumina said net loss swelled to $298 million from $104,000 in the year-ago period. The $600-million acquisition of Solexa in late January, which included a $303 million charge, had the greatest impact on the loss, Illumina said.
  
Illumina said it had around $326 million in cash, cash equivalents, and short-term investments as of March 31.
 
The company said it expects 2007 revenue to be between $305 million and $315 million.
 
Second-quarter revenues are expected to be between $74 million and $78 million.

The Scan

Could Mix It Up

The US Food and Drug Administration is considering a plan that would allow for the mixing-and-matching of SARS-CoV-2 vaccines and boosters, the New York Times says.

Closest to the Dog

New Scientist reports that extinct Japanese wolf appears to be the closest known wild relative of dogs.

Offer to Come Back

The Knoxville News Sentinel reports that the University of Tennessee is offering Anming Hu, a professor who was acquitted of charges that he hid ties to China, his position back.

PNAS Papers on Myeloid Differentiation MicroRNAs, Urinary Exosomes, Maize Domestication

In PNAS this week: role of microRNAs in myeloid differentiation, exosomes in urine, and more.